Comparative Pharmacology
Head-to-head clinical analysis: OPTIRAY 240 versus OPTIRAY 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPTIRAY 240 versus OPTIRAY 300.
OPTIRAY 240 vs OPTIRAY 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OPTIRAY 240 (ioversol) is a nonionic, iodinated, water-soluble radiographic contrast agent that attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during imaging procedures. Its mechanism is physical: the iodine atoms absorb X-rays, providing radiopacity.
Optiray 300 (ioversol) is a nonionic iodinated contrast medium that attenuates X-rays, enhancing vascular and tissue contrast during imaging. It acts by increasing the density of blood vessels and tissues to X-rays, thereby improving visualization of anatomical structures.
Intravenous administration: 50-150 mL of OPTIRAY 240 (iopamidol 240 mg iodine/mL) for adult computed tomography (CT) imaging, typically as a bolus or rapid infusion. Dose depends on procedure and patient size.
Intravenous administration: 50-150 mL per injection (up to 250 mL for CT imaging). Typical adult dose: 1-2 mL/kg body weight (up to 150 mL) given as a bolus or rapid infusion. Intrathecal administration: 8-12 mL for myelography.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe impairment).
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In patients with impaired renal function, half-life may be prolonged significantly (up to 30 hours or more), necessitating dose adjustment or avoidance.
Primarily renal (glomerular filtration); >90% of administered dose excreted unchanged in urine within 24 hours; <1% biliary/fecal.
Primarily renal elimination via glomerular filtration; approximately 95-100% of the administered dose is excreted unchanged in urine within 24 hours. A negligible amount is eliminated via biliary/fecal routes (<1%).
Category C
Category C
Radiological Contrast Agent
Radiological Contrast Agent